Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C…
